In a randomized , double-blinded, placebo-controlled trial that was published in NEJM on March 30, 2022, the early use of Ivermectin (400 mcg per Kg of body weight) daily was not associated with a reduction of hospitalizations or emergency room visits within 28 days among patients who had confirmed COVID-19 disease and at least one risk factor for disease progression. 100 out of 679 patients (14.7%) in the intervention group had a primary-outcome event, as compared with 111 out of 679 patient (16.3%) in the placebo group (relative risk, 0.90; 95% Bayesian credible interval, 0.70 to 1.16).
The results of this well-designed trial do not support using Ivermectin (at least with the dose used in the trial) for patients with COVID-19 disease.
REFERENCE
Reis G. et al. Effect of Early Treatment with Ivermectin among Patients with Covid-19, NEJM; March 30, 2022. DOI: 10.1056/NEJMoa2115869